Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD20-CD19 cCAR in Patients With Relapsed and/or Refractory B Cell Malignancies
Latest Information Update: 04 Nov 2021
At a glance
- Drugs CD20-CD19 cCAR T cell therapy-iCell Gene Therapeutics (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors iCell Gene Therapeutics
Most Recent Events
- 14 Nov 2019 New trial record